Drugs / TAcs
TAcs
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03382262 Comparator | Dec 2017 → Oct 2018 | osteoarthritis, hip | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAcs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03382262 ↗ |
| Known as | TA crystalline suspension | “TA crystalline suspension (TAcs)” PMID 35258839 ↗ Mar 2022 |
| Known as | triamcinolone acetonide crystalline suspension | “triamcinolone acetonide crystalline suspension (TAcs)” NCT03382262 ↗ |
| Known as | Triamcinolone Acetonide Crystalline Suspension (TAcs) | “Triamcinolone Acetonide Crystalline Suspension (TAcs)” NCT03382262 ↗ |
| Route | Other | “Single intra-articular (IA) injection of TAcs 40 mg” NCT03382262 ↗ |